U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118878) titled 'A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants' on July 28.
Brief Summary: In patients with Crohn's disease (CD), fibrosis of the gastrointestinal (GI) tract can result in stricture (stenosis) formation and obstruction of the GI tract, causing obstructive symptoms and often requiring surgical intervention. There are currently no approved therapies for treating fibrostenotic Crohn's disease (FSCD) and therefore, there is an urgent need for safe and effective antifibrotic therapies.
AGMB-129 has shown to be safe in healthy participants with single doses up to 1200 mg and multiple doses up to 200 mg twice daily ...